New chemo timing aims to cut harsh side effects for GI cancer patients
NCT ID NCT06648785
First seen Feb 05, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tests a modified version of standard chemotherapy (capecitabine and oxaliplatin) in 20 people with gastrointestinal cancers. The goal is to see if changing the timing of the drugs reduces side effects like nerve damage, low blood counts, and allergic reactions. Participants will receive the new schedule for at least 3 months, and researchers will track how well it is tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GI CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Vermont
Burlington, Vermont, 05401, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.